Achieve Life Sciences (ACHV) Gains from Sales and Divestitures (2013 - 2025)

Achieve Life Sciences has disclosed Gains from Sales and Divestitures across 13 years of filings, most recently posting $1.7 million for Q4 2025.

• Quarterly Gains from Sales and Divestitures rose 1374.05% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.7 million (up 1374.05% YoY) and the FY2025 annual result came in at $1.7 million, up 1374.05% from the prior year.
• Gains from Sales and Divestitures was little changed at $1.7 million in Q4 2025, from $1.7 million in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $1.7 million in Q3 2025 and troughed at $231.0 in Q3 2021.
• A 5-year average of $321077.1 and a median of $113125.0 in 2024 frame the typical range for Gains from Sales and Divestitures.
• Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures soared 11425.97% — and 2024, when it decreased 19.05%.
• Tracing ACHV's Gains from Sales and Divestitures over 5 years: stood at $231.0 in 2021, then surged by 11425.97% to $26625.0 in 2022, then soared by 424.88% to $139750.0 in 2023, then decreased by 19.05% to $113125.0 in 2024, then soared by 1374.05% to $1.7 million in 2025.
• Business Quant data shows ACHV's Gains from Sales and Divestitures at $1.7 million in Q4 2025, $1.7 million in Q3 2025, and $113125.0 in Q4 2024.